FDA Issues Complete Response Letter For Empagliflozin 2.5 Mg As Adjunct To Insulin For Adults With Type 1 Diabetes, Indicates FDA Is Unable To Approve Application In Current Form; Empagliflozin 2.5 Mg Is Being Developed By Boehringer Ingelheim & Lilly
Benzinga Newsdesk